P‐glycoprotein (PGP), lung resistance‐related protein (LRP) and multidrug resistance‐associated protein (MRP) expression in acute promyelocytic leukaemia

No abstract is available for this paper.

• Publication year

  2000

• Venue

  British Journal of Haematology

• Publication date

  2000-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-2141.2000.01957.xPMID 10792272
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of MRP1 in multidrug resistance in acute myeloid leukemia

  1999influential reference
• P‐glycoprotein, lung resistance‐related protein and multidrug resistance associated protein in de novo acute non‐lymphocytic leukaemias: biological and clinical implications

  1999influential reference
• Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.

  1999influential reference
• Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR 1 / P-Glycoprotein , MRP 1 , and LRP in Acute Myeloid Leukemia . A Southwest Oncology Group Study

  1999influential reference
• P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias.

  1998cited by this paper
• P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias.

  1998cited by this paper
• P170 (Pgp) expression in leukemic cells after therapeutic exposure to arabinosyl cytosine.

  1998cited by this paper
• Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia.

  1998cited by this paper
• P-glycoprotein expression in de novo acute myeloid leukemia.

  1997influential reference
• The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.

  1997influential reference
• Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.

  1997cited by this paper
• Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients

  1997cited by this paper
• Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy

  1997cited by this paper
• P‐glycoprotein (PGP) and lung resistance‐related protein (LRP) expression and function in leukaemic blast cells

  1997influential reference
• Immunocytochemical detection of the multidrug resistance-associated protein and P-glycoprotein in acute myeloid leukemia: impact of antibodies, sample source and disease status

  1997cited by this paper
• Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.

  1997cited by this paper
• Expression of the human major vault protein LRP in acute myeloid leukemia.

  1997cited by this paper
• Major vault protein LRP-related multidrug resistance.

  1996cited by this paper
• Presumed ocular myasthenia and micropsia. A case report.

  1996cited by this paper
• Screening for multidrug resistance in leukemia: cell reactivity to MRK-16 correlates with anthracycline retention and sensitivity of leukemic cells.

  1996cited by this paper
• Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.

  1996influential reference
• Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia.

  1996cited by this paper
• Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia.

  1995cited by this paper
• Chronic lymphocytic leukemia with an interfollicular architecture: avoiding diagnostic confusion with monocytoid B-cell lymphoma.

  1995cited by this paper
• Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia.

  1995influential reference
• Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.

  1995cited by this paper
• Low incidence of MDR1 expression in acute promyelocytic leukaemia

  1995cited by this paper
• Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia.

  1995cited by this paper
• Development of extended multidrug resistance in HL60 promyelocytic leukaemia cells

  1994cited by this paper
• Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses.

  1994cited by this paper
• Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene.

  1994cited by this paper
• Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs.

  1993cited by this paper
• A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives.

  1993cited by this paper
• Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance.

  1993cited by this paper
• Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.

  1992cited by this paper
• Idarubicin (4‐demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: A pilot study of the Italian cooperative group GIMEMA

  1990cited by this paper
• P-glycoproteins in pathology: the multidrug resistance gene family in humans.

  1990cited by this paper
• Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines.

  1989cited by this paper
• Structure and expression of the human MDR (P-glycoprotein) gene family

  1989cited by this paper
• MECHANISMS OF MULTIDRUG RESISTANCE AND IMPLICATIONS FOR THERAPY

  1988cited by this paper
• Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

  1985cited by this paper
• Lithotripsy. Health and Public Policy Committee, American College of Physicians.

  1985cited by this paper

• The biological applications of DNA nanomaterials: current challenges and future directions

  2021cites this paper
• History of Acute Promyelocytic Leukemia

  2021cites this paper
• Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment

  2020cites this paper
• Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts

  2020cites this paper
• What “The Cancer Genome Atlas” database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs

  2019cites this paper
• First-Line Therapy for APL: Chemotherapy-Based Approach

  2018cites this paper
• The success and the challenge of all-trans retinoic acid in the treatment of cancer

  2018cites this paper
• A novel mechanism governing the transcriptional regulation of ABC transporters in MDR cancer cells

  2017cites this paper
• Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model.

  2016cites this paper
• Combined staurosporine and retinoic acid induces differentiation in retinoic acid resistant acute promyelocytic leukemia cell lines

  2014cites this paper
• Estudo da Associação de Genes e Proteínas de Resistência a Múltiplos Fármacos (abcb1/ABCB1, abcc1/ABCC1 e lrp/LRP) com Marcadores Moleculares em Pacientes Portadores de Leucemias Agudas

  2013cites this paper
• Management of Acute Promyelocytic Leukemia in the Elderly

  2013cites this paper
• Immunobiology of Acute Leukemia

  2013cites this paper
• relapsed acute promyelocytic leukemia Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly

  2013cites this paper
• Management of elderly patients with acute promyelocytic leukemia: progress and problems

  2013cites this paper
• Advances in therapies for acute promyelocytic leukemia

  2011cites this paper
• Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy

  2011cites this paper
• Application of Arsenic Trioxide Therapy for Patients with Leukaemia

  2010cites this paper
• Multidrug Resistance Mediated by MDR-ABC Transporters

  2009cites this paper
• Methods and goals for the use of in vitro and in vivo chemosensitivity testing

  2007cites this paper
• Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia

  2007cites this paper
• Targeting multidrug resistance in cancer

  2006cites this paper
• Monoclonal antibodies for the treatment of acute myeloid leukemia.

  2006cites this paper
• Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin.

  2006cites this paper
• Major vault protein/lung resistance-related protein (MVP/LRP) expression in nervous system tumors

  2006cites this paper
• Acute promyelocytic leukemia as a paradigm for targeted therapy.

  2004cites this paper
• Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia.

  2004cites this paper
• Antibody binding capacity for evaluation of MDR‐related proteins in acute promyelocytic leukemia: Onset versus relapse expression

  2004cites this paper
• Changing picture of cellular drug resistance in human leukemia.

  2004cites this paper
• Clinical characteristics, prognostic factors and multidrug‐resistance related protein expression in 36 adult patients with acute promyelocytic leukemia

  2003cites this paper
• Treatment concepts for elderly patients with acute myeloid leukemia

  2003cites this paper
• Acute promyelocytic leukaemia:a review

  2003cites this paper
• New Approach to Vital Analysis of Functional Activity in ABC Transporters (Markers for Multidrug Resistance) in Solid Tumors by the Method of Flow Cytofluorometry

  2003cites this paper
• Multidrug resistance in hematological malignancy.

  2003cites this paper
• P-Glycoprotein Inhibition in Acute Myeloid Leukemia

  2003cites this paper
• Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate

  2003cites this paper
• Expression of cell-surface antigens in acute promyelocytic leukaemia.

  2003cites this paper
• Management of acute promyelocytic leukemia

  2002cites this paper
• Acute promyelocytic leukemia: evolving therapeutic strategies.

  2002cites this paper
• All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

  2002cites this paper
• P‐glycoprotein, lung resistance‐related protein and multidrug resistance‐associated protein in de novo adult acute lymphoblastic leukaemia

  2002cites this paper
• Retinoic acid resistance in acute promyelocytic leukemia

  2002cites this paper
• Drug resistance mechanisms in acute leukemia

  2001cites this paper
• Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.

  2001cites this paper
• Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (MylotargTM CMA‐676)

  2001cites this paper
• Chemotherapy resistance in Acute Leukemia.

  2000cites this paper
• Mediterranean Journal of Hematology and Infectious Diseases Newly Diagnosed Acute Promyelocytic Leukemia

  year unknowncites this paper
• Markers of anticancer drug resistance are predictive of treatment response and outcome in patients with acute myeloid leukemia. Immunologic detection of the drug efflux pumps, P-glycoprotein

  year unknowncites this paper